Seyed Arad Moghadasi

University of Minnesota — United States

Medicine · Health Sciences

11h-index659citations29works5.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(15), Computational Drug Discovery Methods(8), Cytomegalovirus and herpesvirus research(6), HIV Research and Treatment(5), vaccines and immunoinformatics approaches(5)

Publications29 total

Deubiquitinases cleave ubiquitin-fused ribosomal proteins and physically counteract their targeting to the UFD pathway
Molecular Cell·2025Open Access
Structural basis for varying drug resistance of SARS-CoV-2 M <sup>pro</sup> E166 variants
mBio·2025· 4 citedOpen Access
A compact stem-loop DNA aptamer targets a uracil-binding pocket in the SARS-CoV-2 nucleocapsid RNA-binding domain
Nucleic Acids Research·2024· 13 citedOpen Access
A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system
PLoS Pathogens·2024· 10 citedOpen Access
SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening
SLAS DISCOVERY·2024· 5 citedOpen Access
Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system
Antiviral Research·2024· 9 citedOpen Access
Abstract 1217 SARS-CoV-2 Main Protease Inhibitor High-Throughput Screen
Journal of Biological Chemistry·2024Open Access
Highly Specific Sars-Cov-2 Main Protease (Mpro) Mutations Against the Clinical Antiviral Ensitrelvir Selected in a Safe, Vsv-Based System
SSRN Electronic Journal·2024· 2 citedOpen Access
Cellular Assays for Dynamic Quantification of Deubiquitinase Activity and Inhibition
Journal of Molecular Biology·2023· 4 citedOpen Access
A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based system
2023· 9 citedOpen Access
Rapid resistance profiling of SARS-CoV-2 protease inhibitors
npj Antimicrobials and Resistance·2023· 46 citedOpen Access
DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors
Communications Chemistry·2023· 17 citedOpen Access
A comprehensive study of SARS-CoV-2 main protease (M pro ) inhibitor-resistant mutants selected in a VSV-based system
Zenodo (CERN European Organization for Nuclear Research)·2023Open Access
Mitochondrial double-stranded RNA triggers induction of the antiviral DNA deaminase APOBEC3A and nuclear DNA damage
Journal of Biological Chemistry·2023· 7 citedOpen Access
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Science Advances·2023· 164 citedOpen Access
Rapid resistance profiling of SARS-CoV-2 protease inhibitors
2023· 3 citedOpen Access
Rapid resistance profiling of SARS-CoV-2 protease inhibitors
2023· 4 citedOpen Access
Evidence linking APOBEC3B genesis and evolution of innate immune antagonism by gamma-herpesvirus ribonucleotide reductases
eLife·2022· 19 citedOpen Access
Ancestral APOBEC3B Nuclear Localization Is Maintained in Humans and Apes and Altered in Most Other Old World Primate Species
mSphere·2022· 11 citedOpen Access
Author response: Evidence linking APOBEC3B genesis and evolution of innate immune antagonism by gamma-herpesvirus ribonucleotide reductases
2022Open Access
page 1 of 2Next →

Frequent Co-authors

Reuben S. Harris(24), Sofia N. Moraes(9), Emmanuel Heilmann(8), Francesco Costacurta(8), Dorotheé von Laer(8), Jordan T. Becker(7), David Bante(6), Daniel A. Harki(6), Morgan A. Esler(5), Hideki Aihara(5), Ashley A. Auerbach(5), Helge Schöppe(5), Stefanie Rauch(5), Laura Krismer(5), Anna Sauerwein(5), Anne Heberle(5), Toni Rabensteiner(5), Teresa Kaserer(5), Matteo Pavan(4), Davide Bassani(4)